Cover Image
市場調查報告書

Umecrine Mood AB - 產品平台分析

Umecrine Mood AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 310067
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Umecrine Mood AB - 產品平台分析 Umecrine Mood AB - Product Pipeline Review - 2015
出版日期: 2015年07月08日 內容資訊: 英文 22 Pages
簡介

Umecrine Mood AB 是致力於開發對精神障有效的新治療藥之生物製藥公司。特別提供內在性中樞神經系統活性類固醇造成的月經前不適及月經前症候群方面的月經前特有之身心負面症狀之治療法。此外也提供利用GABA類固醇作用的治療方法。

本報告提供Umecrine Mood AB的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Umecrine Mood AB的基本資料

Umecrine Mood AB概要

  • 主要資訊
  • 企業資料

Umecrine Mood AB:R&D概要

  • 主要的治療範圍

Umecrine Mood AB:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Umecrine Mood AB:開發中產品概況

  • 臨床實驗階段有的開發中產品
    • 第二階段有的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Umecrine Mood AB:藥物簡介

  • UC-1010
  • Small Molecule-1 to Target GABAA Receptor for PMDD
  • Small Molecule-2 to Target GABAA Receptor for PMDD

Umecrine Mood AB:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Umecrine Mood AB:最近的開發平台趨勢

Umecrine Mood AB:總公司和子公司的所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07342CDB

Summary

Global Markets Direct's, 'Umecrine Mood AB - Product Pipeline Review - 2015', provides an overview of the Umecrine Mood AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Umecrine Mood AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Umecrine Mood AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Umecrine Mood AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Umecrine Mood AB's pipeline products

Reasons to buy

  • Evaluate Umecrine Mood AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Umecrine Mood AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Umecrine Mood AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Umecrine Mood AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Umecrine Mood AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Umecrine Mood AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Umecrine Mood AB Snapshot
    • Umecrine Mood AB Overview
    • Key Information
    • Key Facts
  • Umecrine Mood AB - Research and Development Overview
    • Key Therapeutic Areas
  • Umecrine Mood AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Umecrine Mood AB - Pipeline Products Glance
    • Umecrine Mood AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Umecrine Mood AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Umecrine Mood AB - Drug Profiles
    • UC-1010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule-1 to Antagonize GABAA Receptor for PMDD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule-2 to Antagonize GABAA Receptor for PMDD
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Umecrine Mood AB - Pipeline Analysis
    • Umecrine Mood AB - Pipeline Products by Target
    • Umecrine Mood AB - Pipeline Products by Route of Administration
    • Umecrine Mood AB - Pipeline Products by Molecule Type
    • Umecrine Mood AB - Pipeline Products by Mechanism of Action
  • Umecrine Mood AB - Recent Pipeline Updates
  • Umecrine Mood AB - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Umecrine Mood AB, Key Information
  • Umecrine Mood AB, Key Facts
  • Umecrine Mood AB - Pipeline by Indication, 2015
  • Umecrine Mood AB - Pipeline by Stage of Development, 2015
  • Umecrine Mood AB - Monotherapy Products in Pipeline, 2015
  • Umecrine Mood AB - Phase II, 2015
  • Umecrine Mood AB - Preclinical, 2015
  • Umecrine Mood AB - Pipeline by Target, 2015
  • Umecrine Mood AB - Pipeline by Route of Administration, 2015
  • Umecrine Mood AB - Pipeline by Molecule Type, 2015
  • Umecrine Mood AB - Pipeline Products by Mechanism of Action, 2015
  • Umecrine Mood AB - Recent Pipeline Updates, 2015

List of Figures

  • Umecrine Mood AB - Pipeline by Stage of Development, 2015
  • Umecrine Mood AB - Monotherapy Products in Pipeline, 2015
  • Umecrine Mood AB - Pipeline by Top 10 Target, 2015
  • Umecrine Mood AB - Pipeline by Top 10 Molecule Type, 2015
  • Umecrine Mood AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top